Therapeutic Plasma Exchange With Enfortumab Vedotin and Pembrolizumab for Treatment of Bladder Cancers
NCT ID: NCT07087860
Last Updated: 2025-12-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
70 participants
INTERVENTIONAL
2025-08-01
2028-08-07
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Enfortumab Vedotin and Pembrolizumab Combined With Radiotherapy in Muscle Invasive Bladder Cancer
NCT06470282
A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
NCT06305767
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
NCT06770582
Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer
NCT06809140
Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract
NCT02925533
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To compare the response rate (overall response rate \[ORR\]) by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 among patients with metastatic bladder cancer (mBCa) who receive therapeutic plasma exchange (TPE) and antibody drug conjugate/immune checkpoint inhibition (ADC/ICI) re-challenge (group A) versus next-line standard of care therapy (group B) after progression on enfortumab vedotin combined with pembrolizumab (EV/pembro). (ReCIPE-B1 \[Groups A and B\]) II. To evaluate the response rate (ORR) by RECIST version 1.1 among patients with metastatic bladder cancer (mBCa) who receive therapeutic plasma exchange (TPE) and antibody drug conjugate (ADC) re-challenge (Cohort C) versus historical controls after progression on ADC. (CAKE ReCIPE \[Cohort C\])
SECONDARY OBJECTIVES:
I. To evaluate and compare the overall survival (OS) of patients receiving TPE and ADC/ICI re-challenge versus next-line standard of care. (ReCIPE-B1 \[Groups A and B\]) II. To evaluate and compare the duration of response (DOR) by RECIST 1.1 between the arms. (ReCIPE-B1 \[Groups A and B\]) III. To evaluate and compare progression-free survival (PFS) by RECIST 1.1 between the arms. (ReCIPE-B1 \[Groups A and B\]) IV. To evaluate safety as assessed per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 in both treatment arms. (ReCIPE-B1 \[Groups A and B\]) V. To evaluate patients' quality of life (QoL) among both treatment arms as assessed by European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Chemotherapy Induced Peripheral Neuropathy 20 (EORTC QLQ-CIPN20) at baseline and every 12 weeks. (ReCIPE-B1 \[Groups A and B\]) VI. To evaluate the overall survival (OS) of patients receiving TPE and ADC re- challenge. (CAKE ReCIPE \[Cohort C\]) VII. To evaluate the duration of response (DOR) by RECIST 1.1. (CAKE ReCIPE \[Cohort C\]) VIII. To evaluate progression-free survival (PFS) by RECIST 1.1. (CAKE ReCIPE \[Cohort C\]) IX. To evaluate safety as assessed per NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. (CAKE ReCIPE \[Cohort C\]) X. To evaluate patients' quality of life (QoL) as assessed by EORTC QLQ-CIPN20 at baseline and every 12 weeks. (CAKE ReCIPE \[Cohort C\])
CORRELATIVE OBJECTIVE:
I. To use circulating exosomes, circulating tumor deoxyribonucleic acid (DNA), and urine tumor DNA for identifying predictive biomarkers of response, progression, or relapse.
OUTLINE: Patients are randomized to 1 of 2 groups. Patients are assigned to Cohort C.
GROUP A: Patients undergo TPE via venous access or central line on days 1-3 of cycles 1-3 and receive enfortumab vedotin intravenously (IV) over 30 minutes on days 3 and 10 of cycles 1-3 and on days 1 and 8 of cycle 4 and beyond and pembrolizumab IV over 30 minutes on day 3 of cycles 1-3 and day 1 of cycles 4 and beyond. Cycles repeat every 21 days in the absence of disease progression of unacceptable toxicity. Patients also undergo computed tomography (CT), positron emission tomography (PET)/CT, or magnetic resonance imaging (MRI) and collection of blood and urine samples throughout the study. Patients may undergo central line placement prior to TPE.
GROUP B: Patients receive physician's choice of standard of care next-line therapy. Patients also undergo CT, PET/CT, or MRI and collection of blood and urine samples throughout the study.
COHORT C: Patients undergo TPE via venous access or central line on days 1-3 of cycles 1-3 only and receive physician's choice of standard of care ADC IV on day 3 of cycles 1-3 and on day 1 of cycles 4 and beyond. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, PET/CT, or MRI and collection of blood and urine samples throughout the study.
After completion of study treatment, patients are followed up every 6 months for up to 5 years.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A (TPE, EV, pembrolizumab)
Patients undergo TPE via venous access or central line on days 1-3 of cycles 1-3 and receive enfortumab vedotin IV over 30 minutes on days 3 and 10 of cycles 1-3 and on days 1 and 8 of cycle 4 and beyond and pembrolizumab IV over 30 minutes on day 3 of cycles 1-3 and day 1 of cycles 4 and beyond. Cycles repeat every 21 days in the absence of disease progression of unacceptable toxicity. Patients also undergo CT, PET/CT, or MRI and collection of blood and urine samples throughout the study. Patients may undergo central line placement prior to TPE.
Biospecimen Collection
Undergo collection of blood and urine samples
Central Venous Cannula Insertion
Undergo central line placement
Computed Tomography
Undergo CT or PET/CT
Enfortumab Vedotin
Given IV
Magnetic Resonance Imaging
Undergo MRI
Pembrolizumab
Given IV
Plasmapheresis
Undergo TPE
Positron Emission Tomography
Undergo PET/CT
Questionnaire Administration
Ancillary studies
Group B (standard of care)
Patients receive physician's choice of standard of care next-line therapy. Patients also undergo CT, PET/CT, or MRI and collection of blood and urine samples throughout the study.
Best Practice
Receive standard of care
Biospecimen Collection
Undergo collection of blood and urine samples
Magnetic Resonance Imaging
Undergo MRI
Positron Emission Tomography
Undergo PET/CT
Questionnaire Administration
Ancillary studies
Cohort C (TPE, ADC)
Patients undergo TPE via venous access or central line on days 1-3 of cycles 1-3 only and receive physician's choice of standard of care ADC IV on day 3 of cycles 1-3 and on day 1 of cycles 4 and beyond. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, PET/CT, or MRI and collection of blood and urine samples throughout the study.
Biospecimen Collection
Undergo collection of blood and urine samples
Central Venous Cannula Insertion
Undergo central line placement
Computed Tomography
Undergo CT or PET/CT
Magnetic Resonance Imaging
Undergo MRI
Plasmapheresis
Undergo TPE
Positron Emission Tomography
Undergo PET/CT
Questionnaire Administration
Ancillary studies
Antibody-Drug Conjugate Therapy
Given IV
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Best Practice
Receive standard of care
Biospecimen Collection
Undergo collection of blood and urine samples
Central Venous Cannula Insertion
Undergo central line placement
Computed Tomography
Undergo CT or PET/CT
Enfortumab Vedotin
Given IV
Magnetic Resonance Imaging
Undergo MRI
Pembrolizumab
Given IV
Plasmapheresis
Undergo TPE
Positron Emission Tomography
Undergo PET/CT
Questionnaire Administration
Ancillary studies
Antibody-Drug Conjugate Therapy
Given IV
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* GROPUS A and B (reCIPE-B1): Histologically proven urothelial carcinoma \[American Joint Committee on Cancer (AJCC) 2017\] of the bladder (BCa) or upper urothelial tract (UTUC), that has progressed despite enfortumab vedotin and pembrolizumab treatment
* NOTE: Primary or secondary progression are allowed, therapies are not required to be concurrent or immediately antecedent to enrollment)
* COHORT C (CAKE ReCIPE): Histologically proven urothelial carcinoma (AJCC 2017) of the bladder (BCa) or upper urothelial tract (UTUC), that has progressed despite ADC AND is otherwise not a candidate for Groups A and B
* NOTE: Patients in Groups A and B who have progressed on that treatment are candidates for this cohort. Such patients must be re-consented and re- enrolled
* Measurable disease per RECIST version (v)1.1
* Eastern Cooperative Oncology Group (ECOG) performance status grade 0, 1, or 2
* Hemoglobin \> 7.0 g/dL (obtained ≤ 30 days prior to registration)
* Platelet count ≥ 75,000/mm\^3 (obtained ≤ 30 days prior to registration)
* Alanine aminotransferase (ALT) OR aspartate transaminase (AST) ≤ 3.5 x upper limit of normal (ULN) OR total bilirubin ≤ 3 x ULN OR direct bilirubin ≤ 3 x ULN (obtained ≤ 30 days prior to registration)
* Estimated glomerular filtration rate (GFR) ≥ 15 ml/min (obtained ≤ 30 days prior to registration)
* Negative pregnancy test ≤ 8 days prior to registration, for persons of childbearing potential only
* Provide written informed consent
* Ability to complete questionnaire(s) by themselves or with assistance
* Willingness to undergo treatment as assigned (group A: TPE + EV/pembro; OR group B: next line standard of care; OR Cohort C TPE + ADC)
* Willingness to provide mandatory blood and fluid specimens for correlative research
* Willingness to provide tissue specimens for correlative research
* Willing to return to enrolling institution for follow-up (during the active monitoring phase of the study)
Exclusion Criteria
* Pregnant persons
* Nursing persons
* Persons of childbearing potential or able to father a child who are unwilling to employ adequate contraception
* Any of the following histologic variants/divergent differentiation: Any amount of neuroendocrine, micropapillary, or signet ring cell features
* Active malignancies (i.e., progressing or requiring treatment change ≤ 24 months before registration) other than the disease being treated under study
* EXCEPTIONS:
* Skin cancer (melanoma or non-melanoma) that is considered completely cured
* Non-invasive cervical cancer that is considered completely cured
* Breast cancer: adequately treated lobular carcinoma in situ or ductal carcinoma in situ considered to have a very low risk of recurrence
* Localized prostate cancer (T1c/T2N0M0):
* Gleason score 6, treated by either surgery or ablation ≤ 24 months prior to registration or untreated and under active surveillance
* Gleason score 3+4 that has been treated (may include surgery or ablation) ≤ 24 months prior to registration and considered to have a very low risk of recurrence (i.e., cT1c or pT2 on prostatectomy specimen)
* History of uncontrolled cardiovascular disease including any of the following ≤ 6 months prior to registration:
* Significant cardiovascular disease \[New York Heart Association (NYHA) class ≥ III\], symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, myocardial infarction, ventricular fibrillation, Torsades de Pointes, cerebrovascular accident, or transient ischemic attack
* Psychiatric illness/social situations (e.g., substance abuse) that would limit compliance with study requirements
* Any condition for which, in the opinion of the investigator, participation would not be in the best interest of the participants (e.g., compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mayo Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jacob J. Orme, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Mayo Clinic
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mayo Clinic in Rochester
Rochester, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Related Links
Access external resources that provide additional context or updates about the study.
Mayo Clinic Clinical Trials
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2025-04887
Identifier Type: REGISTRY
Identifier Source: secondary_id
22-006413
Identifier Type: OTHER
Identifier Source: secondary_id
MC220503
Identifier Type: OTHER
Identifier Source: secondary_id
MC220503
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.